Suchergebnisse - (Person:"Bafadhel, Mona")

PubPharm (149)

31

Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges : A Post-Hoc Analysis of Data from ETHOS

enthalten in: International journal of chronic obstructive pulmonary disease | 2022

von Bafadhel, M. | Rabe, K. | Martinez, F. | +6

32

Discordant diagnostic criteria for pneumonia in COPD trials : a review

enthalten in: European respiratory review : an official journal of the European Respiratory Society | 2021

von Wise, R. | Bafadhel, M. | Crim, C. | +13

33

Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial

enthalten in: bioRxiv.org | 2021

von Ramakrishnan, S. | Nicolau, D. | Langford, B. | +21

34

A Comprehensive Analysis of the Stability of Blood Eosinophil Levels

enthalten in: Annals of the American Thoracic Society | 2021

von Chipps, B. | Jarjour, N. | Calhoun, W. | +7

35

High-dose budesonide for early COVID-19 - Authors' reply

enthalten in: Lancet (London, England) | 2021

von Hobbs, F. | Yu, L. | Saville, B. | +2

CommentOn: Lancet. 2021 Sep 4;398(10303):843-855. - PMID 34388395

36

Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant

enthalten in: BMJ open respiratory research | 2021

von Turnbull, C. | Porter, B. | Evans, S. | +40

37

Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19

enthalten in: bioRxiv.org | 2021

von Baker, J. | Mahdi, M. | Nicolau, D. | +7

38

Renaming COPD exacerbations : the UK respiratory nursing perspective

enthalten in: BMC pulmonary medicine | 2021

von Mwasuku, C. | King, J. | Russell, R. | +1

39

Renaming COPD exacerbations: the UK respiratory nursing perspective

enthalten in: BMC pulmonary medicine | 2021

von Mwasuku, C. | King, J. | Russell, R. | +1

40

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE) : a randomised, controlled, open-label, adaptive platform trial

enthalten in: Lancet (London, England) | 2021

von Yu, L. | Bafadhel, M. | Dorward, J. | +50

CommentIn: Lancet. 2021 Sep 4;398(10303):818-819. - PMID 34388397